摘要
目的 评价干扰素α1b联合拉米夫定治疗慢性乙型肝炎的近期疗效。方法 17例HBVDNA及HBeAg阳性的慢性乙型肝炎病人接受干扰素α1b联合拉米夫定治疗 6个月 ,并与 2 1例仅接受干扰素α1b的病人进行对比。观察联合用药组与单一用药组的谷丙转氨酶、HBVDNA、HBeAg的变化情况及副作用。结果 联合用药组的谷丙转氨酶复常率为 88 2 % ,HBeAg的转阴率为 6 4 7% ;单一用药组分别为 85 7%和5 7 1%。两组比较差异无显著意义。联合用药组的HBVDNA转阴率为 88 2 % ,而单一用药组为 5 7 1% ,两组比较差异有显著意义 (P <0 0 5 )。结论 干扰素α1b和拉米夫定联合应用是一种较安全。
Objective To evaluate the short term therapeutic effect of interferon α1b and lamivudive on the treatment of chronic hepatitis B.Methods Seventeen patients with chronic hepatitis B whose HBeAg and HBV DNA were positive received combined treatment with interferon α1b and lamivudive for 6 months and were compared to 21 cases only with interferon α1b treatment.The changes of ALT,HBV DNA,HBeAg and the side effects of the two groups were observed.Results ALT normalization rate in the combined therapy group was 88.2% after six months of treatment and HBeAg negative rate was 64.7%.In the other group ALT normalization rate and HBeAg negative rate were 85.7% and 57.1% respectively.There is no statistically significant difference between the two groups.HBV DNA negative rate in the combined therapy group was 88.2% and 57.1% in the other group.HBV DNA negative rate in the combined therapy group was significantly higher than that in the other group(P<0.05).Conclusion Combined interferon α1b with lamivudive is safe and effective in the treatment of chronic hepatitis B.
出处
《中国基层医药》
CAS
2002年第11期1001-1002,共2页
Chinese Journal of Primary Medicine and Pharmacy
